Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 237

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 237
---
 2021. Dr. Viney currently serves on the boards of directors of several private companies,
including Seismic and LabCentral. Dr. Viney previously served on the boards of directors of Graphite Bio, Inc. (NASDAQ: GRPH) (now Lenz Therapeutics, Inc. (NASDAQ: LENZ)) from March 2021 to March 2024, Harpoon Therapeutics, Inc. (NASDAQ: HARP) from
July 2020 to June 2023, Finch Therapeutics Group, Inc. (NASDAQ: FNCH) from August 2019 to March 2023 and several private companies. Dr. Viney received her B.Sc. with Honors in biophysical science from the University of East London and her Ph.D. from
the University of London, St. Bartholomew’s Hospital Medical School. We believe Dr. Viney’s substantial leadership experience and scientific background in the biotechnology industry provides her with the appropriate set of skills to serve
as a member of our board of directors.

172

Family Relationships There are no family relationships among any of our executive officers or directors. Composition of our Board of Directors Our business and affairs are managed under the direction of our board of directors, which currently consists of nine members. The primary responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis and additionally as required. Certain members of our board of directors were elected under the provisions of our fourth amended and restated certificate of incorporation and agreements with our stockholders. These board composition provisions will terminate upon the completion of this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our directors. Our nominating and corporate governance committee and our board of directors may therefore consider a broad range of factors relating to the qualifications and background of nominees. Our nominating and corporate governance committee’s and our board of directors’ priority in selecting board members is identification of persons who will further the interests of our stockholders through their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape, professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. Our fifth amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and our amended